---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-033540"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2022-11-23T23:59:59+00:00"
generated_at: "2026-06-21T13:26:12.424980+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Oncocyte director Melinda Griffith to resign from board effective Jan 1, 2023

## Summary
- Resignation not due to any disagreement with company's operations, policies or practices.
- Griffith chairs Nominating/Corporate Governance Committee and serves on Sciences and Technology Committee.
- Effective date January 1, 2023.

## SEC filing metadata
- accession: 0001493152-22-033540
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2022-11-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315222033540/0001493152-22-033540-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315222033540/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-033540
- JSON: https://secwatch.observer/filing/0001493152-22-033540.json
- Plain text: https://secwatch.observer/filing/0001493152-22-033540.txt

## Key facts
- Executive change
  Melinda Griffith resigned as Director at Insight Molecular Diagnostics Inc..
  - Action: resigned
  - Role: Director
  source text: On November 19, 2022, Melinda Griffith notified the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) of her resignation from the Board, effective January 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315222033540/0001493152-22-033540-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.